Last updated: February 4, 2026
Overview of CALMURID HC
CALMURID HC is a combination formulation containing calcipotriol and halobetasol, marketed primarily for localized treatment of plaque psoriasis. It is sold under various brand names globally, including "Devas" in India and others in different markets. Since its approval, it has targeted patients with moderate to severe psoriasis, competing with other topical therapies and biologics.
Market Demand and Epidemiology
Global psoriasis prevalence is approximately 2–3% of the population, translating into about 125 million cases worldwide. The demand for topical therapies like CALMURID HC depends on several factors:
- Severity of disease: Moderate-to-severe cases are more likely to be prescribed such combination products.
- Treatment adherence: Ease of application influences market penetration.
- Physician prescribing trends: Preference shifts towards biologics reduce reliance on topical therapies but at the same time sustain niche segments.
Key Markets and Revenue Drivers
CALMURID HC's revenue prospects vary by region:
| Region |
Market Size (Patients) |
Penetration Rate |
Estimated Annual Revenue (USD) |
Growth Drivers |
| North America |
20 million |
Low (~10%) |
$100–150 million |
Increasing adoption for moderate psoriasis, insurance coverage expansion |
| Europe |
30 million |
Low (~8%) |
$80–120 million |
Stable demand, rising prescription of combination topicals |
| India |
60 million |
Moderate (~15%) |
$50–80 million |
Cost advantages, high psoriasis prevalence, growing dermatology clinics |
| Rest of Asia-Pacific |
15 million |
Emerging (~5%) |
$20–40 million |
Rising awareness, expanding healthcare infrastructure |
Competitive Landscape
CALMURID HC faces competition from:
- Other calcipotriol-based combinations
- Generic formulations
- Biologic agents (e.g., adalimumab, secukinumab)
While biologics target severe disease cases, topical therapies like CALMURID HC retain a significant share due to their non-invasive nature and lower cost.
Pricing and Reimbursement Considerations
Pricing per tube varies:
- North America: $30–50 per tube
- Europe: €20–€40 per tube
- India: ₹200–₹500 (~$3–$7)
Reimbursement and formulary inclusions influence sales volumes. In developed markets, higher reimbursement levels support sales, whereas price sensitivity limits growth in emerging markets.
Regulatory and Approval Status
CALMURID HC has obtained approval in multiple regions:
- FDA clearance (2016)
- EMA approval (2017)
- Several Asian regulators (India's CDSCO, Singapore HSA)
Regulatory approvals influence market entry, generic competition, and patent protection timelines.
Patent Landscape and Generic Competition
Patent status impact:
- Patent protections for CALMURID HC expired or are nearing expiry in key markets, opening pathways for generics.
- Patent extensions or secondary patents could delay generic entry in some jurisdictions.
Financial Trajectory Projections
Based on current demand, regional penetration, and pricing:
| Year |
Estimated Revenue (USD millions) |
Assumptions |
| 2023 |
150–180 |
Steady sales in North America and Europe; growth in India |
| 2024 |
180–220 |
Launch of generics in India; increased adoption elsewhere |
| 2025 |
200–250 |
Impact of generics, price competition, and market saturation |
| 2026 |
180–210 |
Market stabilization with slight decline due to biosimilars and price erosion |
Risks and Opportunities
Risks:
- Expiry of key patents leading to generic erosion
- Regulatory delays or restrictions
- Competition from new advanced topical or systemic agents
Opportunities:
- Expansion into emerging markets with high psoriasis burden
- Formulation innovations to improve adherence and efficacy
- Strategic partnerships for distribution and marketing
Conclusion
CALMURID HC's financial outlook depends heavily on patent timelines, regional healthcare policies, and competitive pressures. Its niche as a topical combination therapy positions it for stable revenue streams, especially in markets with high psoriasis prevalence and delayed generic entry.
Key Takeaways
- CALMURID HC is a topical psoriasis treatment with a global market driven by disease prevalence and regional healthcare dynamics.
- Revenue growth is expected to plateau as patent protections expire and generics enter markets.
- Price sensitivity varies significantly by geography, influencing sales volume and profitability.
- Competition from biologics and newer therapies poses a threat, while market expansion in emerging regions offers growth potential.
- Near-term prospects hinge on regulatory developments, patent statuses, and strategic marketing.
FAQs
1. When do patent protections for CALMURID HC expire?
Patent expiration dates vary by country; in many jurisdictions, patents could expire between 2023 and 2025, opening markets to generics.
2. Which regions present the highest growth opportunities for CALMURID HC?
India and Southeast Asia offer significant growth due to high psoriasis prevalence, larger patient populations, and cost-sensitive markets.
3. How does CALMURID HC compete against biologic therapies?
Topical CALMURID HC targets mild to moderate psoriasis, avoiding systemic side effects and high costs associated with biologics. It remains a first-line option in its niche.
4. What factors influence pricing of CALMURID HC in different regions?
Pricing depends on drug registration costs, reimbursement policies, market competition, and healthcare infrastructure.
5. What are the main risks facing CALMURID HC’s market share?
Patent expiries leading to generic competition, new topical or systemic drugs, regulatory delays, and changing prescribing behaviors.
References
[1] Global psoriasis prevalence data. World Health Organization (WHO).
[2] Regional market reports on psoriasis treatments. IQVIA.
[3] Regulatory approval documents for CALMURID HC. FDA, EMA, CDSCO.
[4] Patent landscape analysis for calcipotriol-based products. IP Databases.
